Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isochlorogenic acid C is a naturally occurring phenolic compound classified as a dicaffeoylquinic acid derivative. It is found in various plants and foods and is produced via the condensation of quinic acid and caffeic acids. Isochlorogenic acid C exhibits multiple bioactivities including antioxidant, anti-inflammatory, antiviral (notably anti-HIV-1 integrase activity), hepatoprotective (anti-HBV), hypolipidemic (lipid-lowering), anti-fibrotic effects, and inhibition of smooth muscle contraction[9][10][6]. Mechanistically, it has been shown to: - Promote reverse cholesterol transport by upregulating LXRα-mediated pathways while downregulating LDLR and CD36 expression in macrophages. - Suppress inflammatory mediators such as iNOS, COX2, IL-1β. - Inhibit Erk/JNK/NF-κB signaling pathways to reduce inflammation-induced synovial proliferation and promote apoptosis in fibroblast-like synoviocytes[7][5]. Preclinical studies suggest potential for treating hyperlipidemia without causing liver steatosis or organ toxicity at tested doses[5]. It is primarily used for research purposes; no approved pharmaceutical formulations are available.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isochlorogenic acid C.